Notice of Proposed Sale · 144/A
Veradermics, Incorporated
MANENYSEEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Veradermics, Incorporated
- Issuer CIK
- 0001827635
- SEC file number
- 001-43097
- Phone
- 228-372-3376
- Person for whose account securities are to be sold
- John W. Childs 2013 Revocable Trust
- Relationships to issuer
- Affiliate
- Street
- 470 James Street
- City
- New Haven
- State / country code
- CT
- Postal code
- 06513
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 100,000 | 10,905,000 | 41,780,136 | 08/12/2026 | NYSE | Glen Eagle Wealth LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Glen Eagle Wealth LLC
- Street
- 4428 C Route 27
- City
- Kingston
- State / country code
- NJ
- Postal code
- 08528
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 02/05/2026 | IPO | Underwriter | 294,117 | N | 02/05/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/14/2026
- Signed
- /s/ John W. Childs
Company context
We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation. Patients and healthcare providers routinely identify the following shortcomings with currently available treatment options: